TYK Medicines, Inc(02410.HK) 가격

TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai and currently employs 163 full-time employees. The company went IPO on 2024-08-20. The firm is primarily focused on small molecule drug development, and its main products include TY-9591, TY-302 and TY-2136. TY-9591 is a third-generation EGFR-TKI with antitumor effects on EGFR mutations. TY-302 is a potent, selective oral CDK4/6 inhibitor developed for the treatment of advanced solid tumors, including breast cancer and prostate cancer. TY-2136b is an internally developed, oral ROS1/NTRK inhibitor for the treatment of solid tumors.